Company: PSTV
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001140361-25-013256
Chunk: 21

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 21
---
ively, the “Purchasers”). The Purchase Agreement provided for the sale and issuance by the Company of an aggregate of 28,042,140 shares of the Company’s Common Stock, or, at the election of each Purchaser, prefunded warrants to purchase Common Stock (the “Prefunded Warrants”), exercisable immediately at an exercise price of $0.001 per share, with each share of Common Stock or Prefunded Warrant accompanied by (i) one Series A common warrant (the “Series A Warrants”) to purchase one share of Common Stock (the “Series A Warrant Shares”), and (ii) one Series B common warrant (the “Series B Warrants,” and together with the Series A Warrants, the “Warrants”) to purchase one share of Common Stock (the “Series B Warrant Shares” and together with the Series A Warrant Shares, the “Warrant Shares”). The combined purchase price of $0.66 for each share of Common Stock or $0.659 for each Prefunded Warrant in the Private Placement, together with one accompanying Series A Warrant and one accompanying Series B Warrant, represented the applicable “Minimum Price” in accordance with Nasdaq Listing Rule 5635(d). The initial exercise price of each Series A Warrant is $1.32 per share of Common Stock. The initial exercise price of each Series B Warrant is $1.98 per share of Common Stock. The Series A Warrants and Series B Warrants are subject to a “reset provision,” pursuant to which the exercise price of the Series A Warrants and Series B Warrants may be reduced to a price not less than $0.132 (the “Floor Price”), subject to appropriate adjustment for any stock dividend, stock split, stock combination, reclassification or similar transaction, and the related number of shares of Common Stock issuable upon exercise may be correspondingly increased. In the event that the exercise price of the Series A Warrants and Series B Warrants is reduced to the Floor Price pursuant to the reset provision, the 28,042,140 outstanding Series A Warrants would become exercisable for an aggregate of up to 280,421,380 shares of Common Stock at the Floor Price and the 28,042,140 outstanding Series B Warrants would become exercisable for an aggregate of up to 420,632,070 shares of Common Stock, or an aggregate of up to 1,261,896,210 shares of Common Stock assuming the Series B Warrants